Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Up 179.6% in February

Synaptogenix, Inc. (NASDAQ:SNPXGet Free Report) was the target of a significant increase in short interest in February. As of February 15th, there was short interest totalling 479,500 shares, an increase of 179.6% from the January 31st total of 171,500 shares. Approximately 2.4% of the shares of the company are sold short. Based on an average daily trading volume, of 742,300 shares, the days-to-cover ratio is currently 0.6 days.

Hedge Funds Weigh In On Synaptogenix

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Synaptogenix by 248.9% during the first quarter. Vanguard Group Inc. now owns 216,836 shares of the company’s stock valued at $1,678,000 after buying an additional 154,688 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Synaptogenix in the 2nd quarter valued at approximately $83,000. Finally, Prelude Capital Management LLC lifted its stake in shares of Synaptogenix by 13.9% in the 2nd quarter. Prelude Capital Management LLC now owns 14,364 shares of the company’s stock valued at $75,000 after purchasing an additional 1,750 shares during the last quarter. 2.79% of the stock is owned by institutional investors.

Synaptogenix Stock Down 4.7 %

SNPX traded down $0.01 during midday trading on Thursday, reaching $0.21. The company had a trading volume of 325,239 shares, compared to its average volume of 993,464. The business has a 50-day moving average of $0.22 and a two-hundred day moving average of $0.31. The company has a market cap of $4.21 million, a P/E ratio of -0.21 and a beta of 1.25. Synaptogenix has a 1 year low of $0.14 and a 1 year high of $1.88.

Synaptogenix Company Profile

(Get Free Report)

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.

Further Reading

Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with's FREE daily email newsletter.